Migraine Market Analysis

Global migraine market share is projected to have a promising growth during the forecast period (2013-2022). Migraine is a neurological disease that is debilitating and characterized by recurring attacks of acute throbbing headache which can last from a few hours to about three days. This may turn worse on movement, thereby preventing the person to perform their daily, normal activities. During the attack, both sides of the face, head or neck gets affected. Migraine can result in a pulsing sensation or severe pain often accompanied by extreme sensitivity to sound and light, vomiting and nausea. The warning symptoms called aura may occur with the headache or before it. These can include tingling in the leg, arm or one part of the face. Resting on the symptoms and sign, migraine is categorized into two types- episodic and chronic. It can be treated through preventive and pain-relieving treatment. The pain-relieving medicines are beneficial to those who have vomiting or nausea associated to their migraine and works quickly. The preventive treatment is used if the migraine occurs frequently, generally above one migraine a week or in case of severe migraine symptoms. There are a couple of factors that can trigger migraine. These include hormonal change in women, alcohol drinks, processed and salty food, and medications such as vasodilators and oral contraceptive.

There are numerous factors that is driving the growth of the migraine market. These factors according to MRFR (Market Research Future) report include global rise in population particularly female population, inaccessibility of permanent cure, rising genericization of drugs, changing lifestyles, rising incidences of hormonal imbalance and increasing stress levels. On the contrary, easy accessibility of generics, over-reliance on OTC (over-the-counter) drugs, low diagnostic rate, regulatory hurdles and poor efficacy of drugs are factors that may restrict the growth of the migraine market.

Avail Free Sample Copy at https://www.marketresearchfuture.com/sample_request/2381

Migraine Market Segmentation

MRFR report offers a complete segmental analysis of the migraine market on the basis of types, treatment types and drug class.

Based on type, it is segmented into chronic and episodic.

Based on treatment type, it is segmented into abortive and preventive.

Based on drug class, the migraine market is segmented into ergots, triptans and others.

Migraine Market Regional Analysis

By region, the migraine market trends covers growth opportunities and latest trends across North America, Europe, Asia Pacific and Middle East and Africa. Of these, North America will have precedence in the migraine market during the forecast period. The factors that can be attributed to the growth of the market in this region include accessibility of various specialty migraine drugs, increasing incidence of migraine and rising healthcare expenditure. In the APAC region, the migraine market will have a favorable growth during the forecast period owing to increasing investments made by the leading players especially in the developing economies namely China and India. In Europe, the migraine market growth is anticipated to have a high growth potential due to growing need for effective migraine treatment in this region.

Migraine Market Competitive Analysis

The global migraine market is fragmented and competitive with the existence of various key players. Leading players in this market are following various strategies for maintaining a stable growth along with increasing profitability in the near future. Some of these strategies include research and development, market collaboration, acquisition, innovation and others.

Migraine Market Key Players

Leading players profiled in the migraine market report include GlaxoSmithKline plc, AstraZeneca plc, OptiNose, Meda, Merck, Luitpold Pharmaceuticals, Kowa Pharmaceuticals America, Klaria, Johnson & Johnson, Pfizer, Inc., Eli Lilly and Company, Eisai Inc., Abbott Laboratories, Inc., Impax Laboratories, Allergan, and others.

Browse Complete Report with TOC at https://www.marketresearchfuture.com/reports/migraine-market-2381

Oct 2018- The US Food and Drug Administration (FDA) has lately approved three drugs to treat migraine. These new medications will help in blocking a protein fragment as well as have shown to stop migraine pain before they start. Of these, the first two migraine inhibiting drugs approved by the FDA include fremanezumab (Ajovy) followed by erenumab (Aimovig). The third CGRP blocker approved by the FDA is galcanezumab (Emgality).